



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

(4)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/978,632	11/25/97	RABBANI	E ENZ-53(C)

RONALD C FEDUS  
ENZO BIOCHEMICAL INC.  
527 MADISON AVENUE  
9TH FLOOR  
NEW YORK NY 10022

HM22/0203

EXAMINER

SCHMIDT, M

ART UNIT

PAPER NUMBER

1635

8

DATE MAILED:

02/03/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

# Office Action Summary

Application No.

08/978,632

Applicant(s)

Rabbani et al.

Examiner

Schmidt

Group Art Unit

1635

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address—

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

## Status

- ☐ Responsive to communication(s) filed on \_\_\_\_\_
- ☐ This action is **FINAL**.
- ☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 1 1; 453 O.G. 213.

## Disposition of Claims

- ☒ Claim(s) 1-24 is/are pending in the application.
- Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- ☒ Claim(s) 1-24 is/are rejected.
- ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- ☐ Claim(s) \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

- ☒ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.
- ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119 (a)-(d)

- ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been received.
- ☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_
- ☐ received in this national stage application from the International Bureau (PCT Rule 1 7.2(a)).

\*Certified copies not received: \_\_\_\_\_

## Attachment(s)

- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- ☒ Notice of Reference(s) Cited, PTO-892
- ☒ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Interview Summary, PTO-413
- ☐ Notice of Informal Patent Application, PTO-152
- ☐ Other \_\_\_\_\_

Office Action Summary

Art Unit: 1635

### DETAILED ACTION

1. An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification (37 CFR 1.78).
2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures: Sequences in this specification and/or the claims are not referenced by a sequence identifier.

### *Double Patenting*

3. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

Art Unit: 1635

4. Claims 2-24 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 2-24 of copending Application Nos.: 08/978633, 08/978634, 08/978635, 08/978636, 08/978637, 08/978638, and 08/978639. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

***Claim Rejections - 35 USC § 112***

5. Claims 1-24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention:

Claims 1-21 are drawn to "a non-naturally occurring construct." The metes and bounds of said construct are not defined because the scope of "non-natural" is not known. The same applies to the language "non-natural entity... and combination."

Claim 8 lacks antecedent basis for "chemical modification."

In claim 10, the language "attached to a single strand or to both strands of said sequence segment" is vague because the structure in light of the construct in claim 1 is not clearly defined, and there is no antecedent basis for "said sequence segment."

In claims 2 and 3, the language "portion" is vague because the structure in light of the construct in claim 1 is not clearly defined.

Art Unit: 1635

6. Claims 1-24 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The construct as taught in the claims broadly encompasses a multitude of constructs for use in a cell to produce a product, the construct comprising at least one modified nucleotide, a nucleotide analog or a non-nucleic acid entity, or a combination of those. The limitations which further define the construct also do so broadly by specifying (1) the construct as linear or circular, (2) the construct as comprising 1, 2 or 3 strands, (3) comprising a terminus, a polynucleotide tail which can hybridize, (4) composed of RNA or DNA or combinations, (5) containing chemically modified nucleotides or analogs, (6) containing non-nucleic acid entities composed of polymers or ligands or a combination, (7) further specifying the natural and synthetic polymers, the synthetic homo- or heteropolymer with a net charge, (8) the construct imparting a "further biological activity" by the modified nucleotide, analog, entity, ligand or combination of those, further defined as nuclease resistance, cell recognition, cell binding, and cellular or nuclear localization or a combination, (9) a ligand attached to one of the modified nucleotides, etc. of claim 1, further described as attached to a "segment" or "tail" of the construct, and further defined as being a macromolecule or small molecule or combination. Claims 22-24 describe a second construct "which when present in a cell produces a product, said construct being bound non-ionically to an entity comprising a chemical modification or a ligand."

Art Unit: 1635

The specification teaches several constructs designed for entry into a cell and expression of one or more sequences and/or proteins to perform a biological function such as antisense inhibition of a product. Antisense inhibition of an HIV protein is exemplified in cell culture by use of a modified expression vector construct. The claimed invention thus reads on constructs in cells and whole organisms, but is not enabled for such use in whole organisms.

There is a high level of unpredictability known in the antisense art for *in vivo* (whole organism) applications. The factors considered barriers to successful delivery of antisense delivery to the organism are: (1) penetration of the plasma membrane of the target cells to reach the target site in the cytoplasm or nucleus, (2) withstanding enzymatic degradation, and (3) the ability to find and bind the target site and simultaneously avoid non-specific binding (see Branch). Despite the synthesis of more resilient, nuclease resistant, oligonucleotide backbones and isolated successes with antisense therapy *in vivo*, the majority of designed antisense molecules still face the challenge of successful entry and localization to the intended target and further such that antisense and other effects can routinely be obtained. Note Flanagan et al. who teach "although numerous reports have cited antisense effects using oligonucleotides added to cell medium, direct proof that oligonucleotides enter cells and affect gene inhibition by an antisense mechanism is still lacking (page48, column 1)."

Specifically, *in vitro* results with one antisense molecule are not predictive of *in vivo* (whole organism) success. *In vitro*, antisense specificity to its target may be manipulated by "raising the temperature or changing the ionic strength, manipulations that are commonly used to

Art Unit: 1635

reduce background binding in nucleic acid hybridization experiments.” (Branch, p. 48) Discovery of antisense molecules with “enhanced specificity” *in vivo* requires further experimentation for which no guidance is taught in the specification. Note Branch who teaches the state of the art for designing an antisense which inhibits a target *in vivo*: it “is very difficult to predict what portions of an RNA molecule will be accessible *in vivo*, effective antisense molecules must be found empirically by screening a large number of candidates for their ability to act inside cells (Branch, p.49).” And in the instant case, the claims read broadly on administration of an antisense inhibitor in any cell, therefore the whole organism included. While the specification teaches cell culture inhibition, no evidence of successful *in vivo* (whole organism) antisense inhibition has been shown, nor do the culture examples correlate with whole organism delivery.

One of skill in the art would not accept on its face the successful delivery of the disclosed antisense molecules *in vivo* in view of the lack of guidance in the specification and the unpredictability in the art. Specifically the specification does not teach (1) stability of the antisense molecule *in vivo*, (2) effective delivery to the whole organism and specificity to the target tissues, (3) dosage and toxicity, nor (4) entry of molecule into cell and effective action therein marked by visualization of the desired treatment effects. These key factors are those found to be highly unpredictable in the art as discussed *supra*. The lack of teaching of these factors in inhibition of the target, coupled to the amount of “trial and error” experimentation involved in the deduction of these results would lead one skilled in the art to necessarily practice an undue amount of experimentation *in vivo*.

Art Unit: 1635

7. Claims 1-24 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

See description of the claimed invention and specification *supra*.

It is not clear from the specification as filed that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. The written description guidelines teach an inverse correlation between the level of predictability in the art and the satisfactory written description in the specification to support a broad genus as claimed.

The instant specification describes in theory a number of potential modified nucleic acid constructs for use in expression of an entity in a cell. The supporting figures provide limited additional disclosure of relevant identifying structural characteristics. The claims, however, broadly encompass "non-naturally occurring...construct(s)," the whole genus of which, or even representative species of which, are not represented by the disclosure as filed so that one of skill in the art could reasonably identify all the members. For example, the figures primarily correspond to expression vector based constructs which are only one facet of the invention as claimed.

ACE 2/1/99



Art Unit: 1635

See the June 15, 1998 (Vol. 63, No. 114, Pages 32639-32645) Federal Register for the interim guidelines for the examination of patent applications under the 35 U.S.C. 112 "Written Description" requirement.

***Claim Rejections - 35 USC § 102***

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

9. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Hsiung et al..

Hsiung et al. teach a vector incorporating synthesized nucleotide sequences for expression of the synthesized sequences in a cell.

10. Claims 1-24 are rejected under 35 U.S.C. 102(e) as being anticipated by Meyer et al..

Meyer et al. teach a covalently linked conjugate of an oligonucleotide (ODN) with a peptide and a carrier or targeting ligand (ODN-peptide-carrier) including a therapeutic oligonucleotide which is capable of selectively binding to a target sequence of DNA, RNA or protein inside a target cell. The invention of Meyer et al. reads on all of the instant claimed limitations (see description of claimed invention above) for a non-naturally occurring construct for production of a product in a cell (in Meyer, an antisense oligonucleotide is produced).

Art Unit: 1635

11. Claim 1 is rejected under 35 U.S.C. 102(e) as being anticipated by Carter et al.

Carter et al. teach a modified recombinant DNA construct of expression of foreign genes in fusion with a synthetic sequence contained in the vector in a cell and therefore reads on the limitations of instant claim 1.

Application/Control Number: 08/978,632


Page 10

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mary M. Schmidt*, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *George Elliott, Ph.D.* may be reached at (703) 308-4003. The examiner's primary, *John LeGuyader*, may be reached at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
JOHN L. LE GUYADER  
PRIMARY EXAMINER  
GROUP 4800  
/600